Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824505) titled 'Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Haihe Biopharma Co., Ltd.
Condition:
Advanced Thymic Carcinoma
Intervention:
Drug: lucitanib 15 mg QD
Drug: lucitanib 10 mg QD
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 16, 2018
Target Sample Size: 74
Countries of Recruitment:
China
To kn...